Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Dendritic Cell Vaccine for Recurrent Glioblastoma
NCT03360708Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2013
- Primary completion
- Jun 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Mayo Clinic. Primary endpoint: Incidence of significant toxicity up to 5 years. Started Nov 2013; status: completed.
02
Drugs
malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03360708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360708.